CARDIOVASCULAR
hamburger

You can make a meaningful impact on patient’s lives

You play a critical role in identifying heart failure progression
early enough to make a difference in your patients’ lives.

Our Latest Advancement in Left Ventricular Assist Device - HeartMate 3™ LVAD

The HeartMate 3™ LVAD with Full MagLev™ Flow Technology has significantly advanced the field of LVAD therapy, setting the standard with innovation and outstanding clinical outcomes. This innovation includes Full MagLev Flow Technology, which maintains gentle blood handling to minimize complications and reduce hemocompatibility-related adverse events.1,2,*

  • More than 15,000 patients worldwide have been implanted3
  • Unparalleled survival, safety, and quality of life outcomes supported by the largest randomized controlled LVAD trial ever conducted1,2,4,5,*

The HeartMate 3 LVAD is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

MOMENTUM 3 study

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating unprecedented** survival and safety outcomes with HeartMate 3™ LVAD.†1


The Highest Survival Rate for any LVAD in a Randomized Controlled Trial1,4,5

79% 2-Year Survival Rate for HeartMate 3 LVAD patients


The Lowest Hemocompatibility-Related Adverse Events of Any LVAD‡,1,2,4,5,††

10% stroke 1% thrombosis after HeartMate 3 LVAD implant.

Immediate, Significant and Sustained Improvement in Functional Capacity and Quality of Life1

80% sustained improvement of HeartMate 3 LVAD patients through 2 years.

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

Abbott has been setting the standard in LVAD therapy for over 20 years.

At Abbott, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping people live their best lives.

When to Refer for Advanced Heart Failure Evaluation

Recognize the symptoms of advanced heart failure6

NYHA Class Class III Class IIIB CLASS IV
(AMBULATORY)
Class IV
(ON INOTROPES)
Markedly symptomatic during daily activities, asymptomatic only at rest Severe limitations, symptoms even at rest
Intermacs Profiles 7 6 5 4 3 2 1
Advanced NYHA III symptoms Exertion limited Exertion intolerant Resting symptoms Stable but inotrope dependent Progressive decline on inotropic support Critical cardiogenic shock

Identify any of the following triggers for referral to a heart failure specialist7

I IV Inotropes
N NYHA IIIB/IV or persistently elevated natriuretic peptides
E End-organ dysfunction (Cr > 1.8 mg/dL or BUN > 43 mg/dL)
E EF ≤ 35%
D Defibrillator shocks
H Hospitalizations > 1 with heart failure
E Edema (or elevated PA pressure) despite escalating diuretics
L Low blood pressure, higher heart rate
P Prognostic medication — progressive intolerance or down-titration GDMT

Additional considerations for referral:

  • CRT non-responder
  • Physical activity limited or impaired quality of life

  • Download the PDF: I-NEED-HELP Clinical Resource

Resources for supporting patients with heart failure

Share this brochure with your advanced heart failure patients so they can learn more about HeartMate 3 LVAD therapy.

Download the PDF: Living a More Active Life with the HeartMate 3 LVAD for the treatment of advanced heart failure

Heartmate 3 Patient Brochure

Our Team is Here to Help

*Compared with HeartMate II.
**Based on HeartMate 3 LVAD highest published survival and lowest published stroke and thrombosis rates in a randomized controlled trial for continuous-flow LVAD category of devices in the U.S. 1,2,4,5
†HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
††Key adverse events include pump thrombosis, stroke and gastrointestinal bleeding.
Indicates a third-party trademark, which is property of its respective owner.

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.
  3. Abbott Data on File" MAT-2002006 v4.0
  4. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.
  5. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
  6. Rogers JG, Boyle AJ, O’Connell JB, et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Design and Rationale of the ROADMAP Clinical Trial. Am Heart J. 2015 Feb;169(2):205-210.e20.
  7. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways [published correction appears in J Am Coll Cardiol. November 13, 2018;72(20):2549]. J Am Coll Cardiol. 2018;71(2):201-230.
  8. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 018;37:1155-1168.
  9. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
  10. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-1757.

Indications, Safety & Warnings

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

MAT-2012011 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.